Laura Michaelis, MD

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Medical Oncology
Hematology

Languages

English

Contact Information

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Laura Michaelis, MD, is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in Acute and Chronic Leukemias, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Bone Marrow Failure Syndromes, and Myeloid Disorders. She graduated from Harvard Medical School in 2000, then completed her internal medicine residency at Brigham and Women’s Hospital in Boston, MA. She received the Arnold Dunne Award for compassionate care in the practice of medicine during her residency. In 2003, Dr. Michaelis relocated to Chicago, IL, where she completed a hematology/oncology fellowship at the University of Chicago. Dr. Michaelis served as an Assistant Professor of Medicine and Program Director of the Hematology and Oncology Fellowship Program at Loyola University Medical Center before joining MCW.

Research Interests

Dr. Michaelis's clinical research focuses on Leukemia, Myelodysplastic Syndromes and Myeloproliferative Neoplasms. She serves as director of inpatient services for the division of Hematology/Oncology and was appointed to be one of the Associate Vice Chairs of the Department of Medicine. Dr. Michaelis is board certified in Hematology and Medical Oncology.

Venetoclax in AML: aiming for just right.

(Michaelis LC.) Blood. 2019 01 03;133(1):3-4 PMID: 30606807 01/05/2019
Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia.

(Michaelis LC, Klepin HD, Walter RB.) Expert Opin Pharmacother. 2018 06;19(8):865-882 PMID: 29697000 04/27/2018
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

(Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR.) Leuk Res. 2018 04;67:17-20 PMID: 29407182 PMCID: PMC6574123 02/07/2018
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

(Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP.) Am J Hematol. 2018 02;93(2):E49-E52 PMID: 29164656 PMCID: PMC5760282 11/23/2017
Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy.

(Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, Atallah E, Hari P, Carlson K.) Acta Haematol. 2018;139(3):171-175 PMID: 29597188 PMCID: PMC6388419 SCOPUS ID: 2-s2.0-85045039013 03/30/2018
Current challenges in the management of essential thrombocythemia.

(Kleman A, Singavi AK, Michaelis LC.) Clin Adv Hematol Oncol. 2017 Oct;15(10):773-783 PMID: 29040257 10/19/2017
Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis.

(Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B.) Am J Hematol. 2017 Sep;92(9):E563-E565 PMID: 28631379 SCOPUS ID: 2-s2.0-85021972988 06/21/2017
Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.

(Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M.) Biol Blood Marrow Transplant. 2017 Aug;23(8):1295-1302 PMID: 28412518 SCOPUS ID: 2-s2.0-85019639994 04/17/2017
A Fatal Case of Erdheim-Chester Disease with Hepatic Involvement.

(Balasubramanian G, Modiri A, Affi M, Hagen CE, Batdorf B, Oshima K, Michaelis L, Saeian K.) ACG Case Rep J. 2017;4:e95 PMID: 28798943 PMCID: PMC5541758 08/12/2017
Risk stratification in myelofibrosis: the quest for simplification.

(Michaelis LC.) Haematologica. 2017 01;102(1):2-3 PMID: 28040786 PMCID: PMC5210226 01/04/2017
Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms.

(Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC.) Bone Marrow Transplant. 2016 Apr;51(4):617-8 PMID: 26726940 SCOPUS ID: 2-s2.0-84953295752 01/05/2016
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

(Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V.) Biol Blood Marrow Transplant. 2016 Mar;22(3):432-40 PMID: 26493563 PMCID: PMC5030817 SCOPUS ID: 2-s2.0-84950996639 10/24/2015